Mariya V Sivay1, Maoji Li, Estelle Piwowar-Manning, Yinfeng Zhang, Sarah E Hudelson, Mark A Marzinke, Rivet K Amico, Andrew Redd, Craig W Hendrix, Peter L Anderson, Kevin Bokoch, Linda-Gail Bekker, Frits van Griensven, Sharon Mannheimer, James P Hughes, Robert Grant, Susan H Eshleman. 1. *Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; †Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA; ‡Department of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, MI; §Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; ‖Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD; ¶Division of Clinical Pharmacology, Johns Hopkins University School of Medicine, Baltimore, MD; #Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO; **FHI 360, Durham, NC; ††Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; ‡‡Department of Epidemiology and Biostatistics, University of California San Francisco School of Medicine, San Francisco, CA; §§Departments of Medicine and Epidemiology, Columbia University Affiliation at Harlem Hospital, New York, NY; ‖‖Columbia University Mailman School of Public Health, New York, NY; ¶¶Department of Biostatistics, University of Washington, Seattle, WA; and ##University of California, San Francisco Gladstone Institutes, San Francisco, CA.
Abstract
BACKGROUND: HIV Prevention Trials Network (HPTN) 067/ADAPT evaluated tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) pre-exposure prophylaxis (PrEP) in women (South Africa) and men who have sex with men (Thailand, US). Participants received once-weekly directly observed therapy (DOT) of TDF/FTC, and were then randomized to daily, time-driven, or event-driven PrEP. This report describes characterization of 12 HIV seroconversion events in this trial. METHODS: HIV rapid testing was performed at study sites. Retrospective testing included fourth generation assays, HIV RNA testing, Western blot, an HIV-1/2 discriminatory assay, resistance testing, and antiretroviral drug testing. RESULTS: Six of the 12 seroconverters received TDF/FTC in the DOT phase, but were not randomized (3 were acutely infected at enrollment; 2 were infected during the DOT phase; 1 was not randomized because of pregnancy). One of the 6 randomized participants had acute infection at randomization but was not diagnosed for 3-4 months because HIV rapid tests were nonreactive; continued daily PrEP use was associated with false-negative antibody tests and low HIV RNA levels. The 5 participants infected after randomization included 4 with low adherence to the PrEP regimen, and one who reported a 7-day period without dosing before infection. Three participants had TDF/FTC resistance (M184I, K65R), including 2 who received only 4 once-weekly TDF/FTC doses; most TDF/FTC mutations were detected by next generation sequencing only. CONCLUSIONS: In HPTN 067/ADAPT, participants who acquired HIV infection had infrequent PrEP dosing or low/suboptimal adherence. Sensitive assays improved detection of HIV infection and drug resistance. Drug resistance was observed with limited PrEP exposure.
RCT Entities:
BACKGROUND: HIV Prevention Trials Network (HPTN) 067/ADAPT evaluated tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) pre-exposure prophylaxis (PrEP) in women (South Africa) and men who have sex with men (Thailand, US). Participants received once-weekly directly observed therapy (DOT) of TDF/FTC, and were then randomized to daily, time-driven, or event-driven PrEP. This report describes characterization of 12 HIV seroconversion events in this trial. METHODS: HIV rapid testing was performed at study sites. Retrospective testing included fourth generation assays, HIV RNA testing, Western blot, an HIV-1/2 discriminatory assay, resistance testing, and antiretroviral drug testing. RESULTS: Six of the 12 seroconverters received TDF/FTC in the DOT phase, but were not randomized (3 were acutely infected at enrollment; 2 were infected during the DOT phase; 1 was not randomized because of pregnancy). One of the 6 randomized participants had acute infection at randomization but was not diagnosed for 3-4 months because HIV rapid tests were nonreactive; continued daily PrEP use was associated with false-negative antibody tests and low HIV RNA levels. The 5 participants infected after randomization included 4 with low adherence to the PrEP regimen, and one who reported a 7-day period without dosing before infection. Three participants had TDF/FTC resistance (M184I, K65R), including 2 who received only 4 once-weekly TDF/FTC doses; most TDF/FTC mutations were detected by next generation sequencing only. CONCLUSIONS: In HPTN 067/ADAPT, participants who acquired HIV infection had infrequent PrEP dosing or low/suboptimal adherence. Sensitive assays improved detection of HIV infection and drug resistance. Drug resistance was observed with limited PrEP exposure.
Authors: Robert M Grant; Javier R Lama; Peter L Anderson; Vanessa McMahan; Albert Y Liu; Lorena Vargas; Pedro Goicochea; Martín Casapía; Juan Vicente Guanira-Carranza; Maria E Ramirez-Cardich; Orlando Montoya-Herrera; Telmo Fernández; Valdilea G Veloso; Susan P Buchbinder; Suwat Chariyalertsak; Mauro Schechter; Linda-Gail Bekker; Kenneth H Mayer; Esper Georges Kallás; K Rivet Amico; Kathleen Mulligan; Lane R Bushman; Robert J Hance; Carmela Ganoza; Patricia Defechereux; Brian Postle; Furong Wang; J Jeff McConnell; Jia-Hua Zheng; Jeanny Lee; James F Rooney; Howard S Jaffe; Ana I Martinez; David N Burns; David V Glidden Journal: N Engl J Med Date: 2010-11-23 Impact factor: 91.245
Authors: Christoph D Spinner; Christoph Boesecke; Alexander Zink; Heiko Jessen; Hans-Jürgen Stellbrink; Jürgen Kurt Rockstroh; Stefan Esser Journal: Infection Date: 2015-10-15 Impact factor: 3.553
Authors: Lane R Bushman; Jennifer J Kiser; Joseph E Rower; Brandon Klein; Jia-Hua Zheng; Michelle L Ray; Peter L Anderson Journal: J Pharm Biomed Anal Date: 2011-06-06 Impact factor: 3.935
Authors: Craig W Hendrix; Adriana Andrade; Namandjé N Bumpus; Angela D Kashuba; Mark A Marzinke; Ayana Moore; Peter L Anderson; Lane R Bushman; Edward J Fuchs; Ilene Wiggins; Christine Radebaugh; Heather A Prince; Rahul P Bakshi; Ruili Wang; Paul Richardson; Eugenie Shieh; Laura McKinstry; Xin Li; Deborah Donnell; Vanessa Elharrar; Kenneth H Mayer; Kristine B Patterson Journal: AIDS Res Hum Retroviruses Date: 2015-10-15 Impact factor: 2.205
Authors: Ariane van der Straten; Jonathan Stadler; Ellen Luecke; Nicole Laborde; Miriam Hartmann; Elizabeth T Montgomery Journal: J Int AIDS Soc Date: 2014-09-08 Impact factor: 5.396
Authors: Virginia A Fonner; Sarah L Dalglish; Caitlin E Kennedy; Rachel Baggaley; Kevin R O'Reilly; Florence M Koechlin; Michelle Rodolph; Ioannis Hodges-Mameletzis; Robert M Grant Journal: AIDS Date: 2016-07-31 Impact factor: 4.177
Authors: Ross S Milne; Rachel A Silverman; Ingrid A Beck; Jennifer Mckernan-Mullin; Wenjie Deng; Thomas R Sibley; Sandra Dross; James N Kiarie; Samah R Sakr; Robert W Coombs; Michael H Chung; Lisa M Frenkel Journal: AIDS Date: 2019-05-01 Impact factor: 4.177
Authors: Robert M Grant; Sharon Mannheimer; James P Hughes; Yael Hirsch-Moverman; Avelino Loquere; Anupong Chitwarakorn; Marcel E Curlin; Maoji Li; K Rivet Amico; Craig W Hendrix; Peter L Anderson; Bonnie J Dye; Mark A Marzinke; Estelle Piwowar-Manning; Laura McKinstry; Vanessa Elharrar; Michael Stirratt; James F Rooney; Susan H Eshleman; Janet M McNicholl; Frits van Griensven; Timothy H Holtz Journal: Clin Infect Dis Date: 2018-05-17 Impact factor: 9.079
Authors: Kristen Underhill; Kate M Guthrie; Christopher Colleran; Sarah K Calabrese; Don Operario; Kenneth H Mayer Journal: Arch Sex Behav Date: 2018-01-11
Authors: Linda-Gail Bekker; Surita Roux; Elaine Sebastien; Ntando Yola; K Rivet Amico; James P Hughes; Mark A Marzinke; Craig W Hendrix; Peter L Anderson; Vanessa Elharrar; Michael Stirratt; James F Rooney; Estelle Piwowar-Manning; Susan H Eshleman; Laura McKinstry; Maoji Li; Bonnie J Dye; Robert M Grant Journal: Lancet HIV Date: 2017-10-03 Impact factor: 12.767
Authors: Susan H Eshleman; Estelle Piwowar-Manning; Mariya V Sivay; Barbara Debevec; Stephanie Veater; Laura McKinstry; Linda-Gail Bekker; Sharon Mannheimer; Robert M Grant; Margaret A Chesney; Thomas J Coates; Beryl A Koblin; Jessica M Fogel Journal: J Clin Virol Date: 2018-01-11 Impact factor: 3.168